why choose us

First received: February 27, 2023

Clinical Trial: Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Endometrial Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Brief Summary: To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.

Read more